Welcome to our dedicated page for InspireMD news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on InspireMD stock.
InspireMD develops and commercializes carotid stent systems built around its MicroNet stent platform for carotid artery disease and stroke prevention. News for NSPR centers on CGuard Prime and CGuard product commercialization, U.S. and international demand, FDA interactions, IDE approvals, pivotal studies for TCAR-related use, and product quality actions such as the CGuard Prime 135 cm delivery-system recall.
Company updates also cover quarterly financial results, hospital adoption and procedure experience, publications from C-GUARDIANS studies, investor conference participation, and capital-market communications tied to its Nasdaq-listed common stock.
InspireMD (NSPR) granted 23,764 shares of restricted stock as Nasdaq Rule 5635(c)(4) inducement awards to a new non-executive employee, effective September 2, 2026.
The awards were issued under the company’s 2024 Inducement Plan, separate from the 2021 Equity Incentive Plan, and are solely for new hires. Vesting is time-based and contingent on continued employment, with 11,264 shares vesting in three installments from January 14, 2027 to January 14, 2029, 12,000 shares vesting in two equal installments on January 20, 2027 and January 20, 2028, and 500 shares vesting in three installments from June 12, 2027 to June 12, 2029.
InspireMD (NSPR) will present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14 at 2:30 p.m. Eastern Time.
A live audio webcast and archived replay will be accessible via the investors page on the company’s website. Investors can contact their institutional representative to request a meeting or obtain additional conference details.
InspireMD (Nasdaq:NSPR) reported second quarter 2026 revenue of $1.77 million, essentially flat versus Q2 2025, as 21% international growth was offset by a voluntary U.S. recall of the CGuard Prime 135 cm delivery system, which drove negative U.S. revenue of $(0.35) million.
Recall-related customer credits of $734,000 and a $612,000 inventory impairment contributed to a gross loss of $0.77 million, versus gross profit of $0.31 million a year ago; non-GAAP adjusted gross profit was $0.57 million. Operating expenses rose modestly to $13.67 million, and net loss widened to $14.32 million ($0.17/share). Cash, cash equivalents and marketable securities were $30.42 million at June 30, 2026, down from $54.21 million at year-end 2025.
The company began actions expected to generate about $9 million in annual cost savings, reported strong 30-day CGUARDIANS II TCAR outcomes with no deaths, strokes, MIs or stent thrombosis, initiated CGUARDIANS III enrollment, progressed design changes to the recalled system, and continues to anticipate FDA decisions on its CGuard platforms later in 2026.
InspireMD (Nasdaq:NSPR) announced it will release its second quarter 2026 financial results on Monday, August 17, 2026. In conjunction, the company will host a conference call and live audio webcast at 8:30 a.m. Eastern Time to review results and recent highlights.
Investors can participate by phone after registering through an online form, which provides dial-in details and a personal PIN via email. A live webcast and archived replay will be accessible through the Investors section of InspireMD’s website, with participants encouraged to register at least 15 minutes before the call.
InspireMD (Nasdaq:NSPR) approved inducement grants totaling 221,666 shares of restricted stock to a new non-executive employee, with a grant date of August 3, 2026. The awards were made outside the 2021 Equity Incentive Plan under InspireMD’s 2024 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The restricted stock vests in tranches: 56,666 shares in two equal installments on January 10, 2027 and 2028; 40,000 shares in three annual installments on January 16, 2027, 2028 and 2029; and 125,000 shares in three annual installments starting on the first anniversary of the grant date, all subject to continued employment.
InspireMD (Nasdaq: NSPR) appointed experienced commercial leader Kathleen (Kathy) Kennedy as Senior Vice President of Global Sales and Marketing, reporting to CEO Marvin Slosman. Kennedy brings over 30 years of medical device sales leadership, with deep expertise in carotid intervention and carotid stenting.
She previously supported the initial U.S. launch of CGuard Prime at InspireMD and returns with established relationships across vascular, neurovascular and cardiovascular physician communities, and health systems involved in carotid therapies. According to InspireMD, her appointment supports preparations for the potential U.S. approval, commercial relaunch and scaling of the CGuard platform, including CGuard Prime 80cm for TCAR procedures.
InspireMD (Nasdaq:NSPR) approved inducement grants of 91,161 restricted shares for six new non-executive employees under its 2024 Inducement Plan. These equity awards are granted outside the 2021 Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock vests over three years: one-third after the first anniversary, and the remaining two-thirds in equal installments on the second and third anniversaries, subject to the employees’ continued employment with InspireMD.
InspireMD (Nasdaq:NSPR) reported 30-day results from the CGUARDIANS II pivotal trial of its CGuard Prime 80 cm stent for TCAR procedures. In 50 patients, acute device success was 100%, with no deaths, strokes, myocardial infarctions, stent thrombosis, and complete stent patency in evaluable subjects.
The prospective, multi-center, single-arm study ran across 11 sites in high-risk patients using the FDA-cleared ENROUTE TCAR neuroprotection system. A PMA supplement for CGuard Prime 80 cm is under FDA review, with potential U.S. approval in H2 2026, targeting over 35,000 annual TCAR procedures.
InspireMD (Nasdaq:NSPR) enrolled the first patient in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system for use with the CGuard Prime 80 cm stent in TCAR procedures.
The prospective, multi-center, single-arm trial plans to enroll about 103 high-risk carotid stenosis patients.
InspireMD (Nasdaq: NSPR) will present at the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026 at 4:20 pm PT. A live audio webcast and archived recording will be available via the company’s Investors page at the provided investor website link.